Intravenous Solutions Market To Reach $28.2 Billion By 2033

November 2025 | Report Format: Electronic (PDF)

Intravenous Solutions Market Growth & Trends

The global intravenous solutions market size is anticipated to reach USD 28.2 billion by 2033, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 9.36% from 2025 to 2033. The high prevalence of preterm births, especially in emerging economies such as India and China, is expected to drive market growth during the forecast period. According to WHO, 1 in 10 babies are born preterm, and this is a global concern. Thus, the high incidence of preterm births in emerging economies, improved healthcare infrastructure, and growing healthcare expenditure & patient awareness are expected to be high impact rendering drivers of the market during the forecast period.

The use of parenteral lipid emulsions is driven by the extensive focus of various authorities to limit preterm birth mortality. As of 2021, the preterm birth rate in the U.S. was about 10.5%. Moreover, the annual societal, and economic cost was estimated at USD 25.2 billion for preterm births. Hence, the presence of many neonates requiring supplementary postbirth nutrition is expected to boost the market demand over the forecast period.

In addition, several studies justify the use of parenteral nutrition for patients suffering from malnutrition problems, which increased during the pandemic, leading to market growth. For instance, according to an article published in the Journal of the Academy of Nutrition and Dietetics, many patients admitted to the ICU for COVID-19 treatment suffer from acute malnourishment. Hence, the usage of parenteral nutrition products is expected to increase in the market during the pandemic.

In COVID-19-positive patients, high deficiency of specific micronutrients and vitamins has been reported to be detrimental. Thus, intravenous administration is recommended in such patients to meet the recommended dietary intake. Physicians and nutrition specialists preferred parenteral nutrition over enteral nutrition in COVID-19 patients since enteral nutrition specifically requires the setup of nasogastric tubes, which hampers the noninvasive ventilation provided to COVID-19 patients. The increased risk of nutritional solution aspiration and underfeeding in hospitalized patients for COVID-19 has led to increased adoption of parenteral nutrition.

key Request a free sample copy or view report summary: Intravenous Solutions Market Report

Intravenous Solutions Market Report Highlights

In 2024, the Total Parenteral Nutrition (TPN) segment held a dominant market share of 66.3% and is projected to experience the highest growth rate (CAGR of 8.2%) during the forecast period. TPN involves administering a comprehensive set of nutrients through an intravenous (IV) technique
In 2024, the market was led by the single-dose amino acid solution segment, holding a significant share of 31.6%. Studies have shown that single-dose amino acids offer a complete protein source, are easily customizable with other parenteral formulations, and are straightforward to administer
In 2024, North America held a dominant market share of 40.9%, credited to key players, favorable regulations, and strong reimbursement in countries like the U.S. Assure Infusions, Inc. announced a USD 20 million investment to build an advanced manufacturing facility in Bartow, Florida, addressing the IV solutions demand-supply gap in the U.S.